Design and Optimization of a Polyethylene Oxide-Based Matrix Tablet of Metoprolol Succinate Using Design Expert Software
Pharmaceutical Science-Pharmaceutics
DOI:
https://doi.org/10.22376/ijlpr.2023.13.2.P144-P153Keywords:
Metoprolol succinate, PEO WSR 301, PEO WSR 303, sustained release, design expertAbstract
Hypertension is a common lifestyle disorder, the prevalence of which advances with age. In the case of antihypertensive therapy, patient compliance is hampered, especially in geriatric patients, if the dose is b.i.d or more, as it is difficult for the patient to remember and take medicine at a scheduled time. The present study involves the fabrication of a sustained-release matrixdesigned tablet using a combination of polyethylene oxide (PEO) polymers and metoprolol succinate as the model drug. The tablet is optimized and evaluated for its in-vitro release using the Design expert software. Polyethylene oxide is a non-ionic hydrophilic polymer which is directly compressible. Polyox WSR 301 and 303 grades have been used in the study to get the desired sustained release of 12 h. The formulations were analysed for various pre-compression and post-compression characteristics. The polymers Polyox WSR 301 and 303 influence drug release are measured using a 32 factorial design where the concentration of drug released at various time points has been analysed statistically as a response. Response surface plots demonstrate and depict the effect of the variables, thus aiding in optimization. All the formulated batches exhibited acceptable pre and post-compression characteristics. The optimized formulation M05 showed a sustained drug release up to a 12 h period. Thus polyethylene oxide can be used as an excellent sustained-release matrix polymer due to its ability to gel and prolong drug release from a matrix. Due to their molecular weight, a combination of two grades of polyethylene oxide helps reinforce the drug release.
References
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertens (Dallas. 2003;42(6):1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2, PMID 14656957 Dec;42(6):1206–52.
Fields LE. Mortality from stroke and ischemic heart disease increases exponentially with blood pressure. Hypertension. 2004 Apr;43(4):e28;; author reply e28. doi: 10.1161/01.HYP.0000121366.89530.1c, PMID 14981060.
Cilli E, Ranieri J, Guerra F, Ferri C, Di Giacomo D. Cardiovascular disease, self-care and emotional regulation processes in adult patients: balancing unmet needs and quality of life. Biopsychosoc Med. 2022 Sep 30;16(1):20. doi: 10.1186/s13030-022-00249-y, PMID 36180951.
Ross S, Walker A, MacLeod MJ. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. J Hum Hypertens. 2004 Sep 1;18(9):607-13. doi: 10.1038/sj.jhh.1001721, PMID 15029218.
Papadopoulos DP, Papademetriou V. Metoprolol succinate combination in the treatment of hypertension. Angiology. 2009 Nov 24;60(5):608-13. doi: 10.1177/0003319708326450, PMID 19033265.
Falkner B, Francos G, Kushner H. Metoprolol succinate, a selective beta-adrenergic blocker, has no effect on insulin sensitivity. J Clin Hypertens (Greenwich). 2006 May;8(5):336-43. doi: 10.1111/j.1524-6175.2006.05247.x, PMID 16687942.
Deshmukh VN, Singh SP SD. Formulation and evaluation of sustained release metoprolol succinate tablet using hydrophilic gums as release modifiers. Int J Pharm Tech Res. 2009;1:159-63.
Mutschler E, Knauf H. Current status of sustained release formulations in the treatment of hypertension. An overview. Clin Pharmacokinet. 1999;37;Suppl 1:1-6. doi: 10.2165/00003088-199937001-00001, PMID 10491727.
Plosker GL, Clissold SP. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Drugs. 1992 Mar;43(3):382-414. doi: 10.2165/00003495-199243030-00006, PMID 1374320.
Vidyadhara S, Sasidhar RLC, Nagaraju R. Design and development of polyethylene oxide based matrix tablets for verapamil hydrochloride. Indian J Pharm Sci. 2013 Mar;75(2):185-90. PMID 24019567.
Maderuelo C, Zarzuelo A, Lanao JM. Critical factors in the release of drugs from sustained release hydrophilic matrices. J Control Release. 2011 Aug 25;154(1):2-19. doi: 10.1016/j.jconrel.2011.04.002, PMID 21497624.
Nardi-Ricart A, Nofrerias-Roig I, Suñé-Pou M, Pérez-Lozano P, Miñarro-Carmona M, García-Montoya E, et al. Formulation of sustained release hydrophilic matrix tablets of tolcapone with the application of sedem diagram: influence of tolcapone’s particle size on sustained release. Pharmaceutics. 2020 Jul 17;12(7):674. doi: 10.3390/pharmaceutics12070674, PMID 32708961.
Timmins P, Desai D, Chen W, Wray P, Brown J, Hanley S. Advances in mechanistic understanding of release rate control mechanisms of extended-release hydrophilic matrix tablets. Ther Deliv. 2016 Aug;7(8):553-72. doi: 10.4155/tde-2016-0026, PMID 27444495.
Maggi L, Segale L, Torre ML, Ochoa ME, Conte U. Dissolution behaviour of hydrophilic matrix tablets containing two different polyethylene oxides (PEOs) for the controlled release of a water-soluble drug. Dimensionality study. Biomaterials. 2002 Feb;23(4):1113-9. doi: 10.1016/s0142-9612(01)00223-x, PMID 11791914.
Shojaee S, Emami P, Mahmood A, Rowaiye Y, Dukulay A, Kaialy W, et al. An investigation on the effect of polyethylene oxide concentration and particle size in modulating theophylline release from tablet matrices. AAPS PharmSciTech. 2015 Dec 14;16(6):1281-9. doi: 10.1208/s12249-015-0295-z, PMID 25771738.
Apicella A, Cappello B, Del Nobile MA, La Rotonda MI, Mensitieri G, Nicolais L. Poly(ethylene oxide) (PEO) and different molecular weight PEO blends monolithic devices for drug release. Biomaterials. 1993 Jan;14(2):83-90. doi: 10.1016/0142-9612(93)90215-n, PMID 8435462.
Dighe PP, Hm T. Design and statistical optimization of a bilayered tablet of metoprolol succinate sustained release and atorvastatin calcium immediate release: once a day formulation in the management of hypertension. Asian J Pharm Clin Res. 2018 Mar 1;11(3):293. doi: 10.22159/ajpcr.2018.v11i3.23528.
Dighe PP, Tank HM. Formulation development and statistical optimization of A bilayer tablet of bosentan monohydrate and sildenafil citrate in management of pulmonary arterial hypertension. Int J Appl Pharm. 2019 Feb 12;11(2):239-46. doi: 10.22159/ijap.2019v11i2.30927.
Venkateswarlu K. Formulation and evaluation of sustained release matrix tablets of repaglinide. Bangladesh Pharm J. 2016 Aug 10;19(1):92-9. doi: 10.3329/bpj.v19i1.29244.
Nalawade V, Miranda O, Kushare A, Mhadgut A. Study to understand factors governing dissolution of paracetamol tablets using design Expert® software. Indian Drugs. 2018 Aug 28;55(8):31-7. doi: 10.53879/id.55.08.10958.
Rockville M. Harmonized Tripartide guidelines for stability testing of new drug substances and products Q1a (R2). In: International Conference of Harmonization (Ich) U S A Pharmacopoeial Convention. Inc. 2003. p. 6.
Patel D, Prajapati B. Extended release micro-pellets of chiral molecule of metoprolol succinate by fluid bed technology. Int J Pharm Sci Drug Res. 2017 Jan 30;9(1). doi: 10.25004/IJPSDR.2017.090102.
Oza NA, Makwana A, Gohil TA SP. Statistical optimization of miconazole nitrate microemulgel by using 23 full factorial design. Int J Pharm Sci Drug Res. 2021;13(01):15-23.
Şenyiğit Z, Özyazıcı M, Rençber S. Stability studies of compression coated ornidazole tablets for colon specific drug delivery. J Res Pharm. 2018 Nov 29;23(1):34-43.
Chime SA, Onunkwo GC OI. Kinetics and mechanisms of drug release from swellable and Non swellable matrices: a review. Res J Pharm Biol Chem Sci. 2013;4(2):97-103.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Pearl Dighe, Mangirish Deshpande
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
